Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.87 |
| ▸ | BACE1 | P56817 | 3/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.80 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.80 |
| ▸ | STAT3 | P40763 | 2/20 | 0.80 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.80 |
| ▸ | RELA | Q04206 | 2/20 | 0.80 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.80 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | CA12 | O43570 | 2/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | CA3 | P07451 | 2/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.73 |
| ▸ | CA4 | P22748 | 2/20 | 0.73 |
| ▸ | CA6 | P23280 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680675 | 1.00 | GSK3B (0.87) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| SCHEMBL29855588 | 1.00 | GSK3B (0.87) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| SCHEMBL29370884 | 1.00 | GSK3B (0.87) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| SCHEMBL242412 | 1.00 | GSK3B (0.87) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| SCHEMBL3433171 | 1.00 | GSK3B (0.87) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| Methylcurcumin SCHEMBL9907002 | 0.96 | GSK3B (0.81) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| SCHEMBL22902413 | 0.96 | GSK3B (0.81) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| SCHEMBL16888009 | 0.96 | GSK3B (0.81) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| Demethoxycurcumin SCHEMBL9907007 | 0.95 | GSK3B (0.83) | GSK3BBACE1CYP2D6NFKB1CYP1A2 | |
| Demethoxycurcumin SCHEMBL29374534 | 0.95 | GSK3B (0.83) | GSK3BBACE1CYP2D6NFKB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122913-A1 | COMBINATION OF CURCUMINOIDS AND MTOR INHIBITORS FOR THE TREATMENT OF TAUOPATHIES | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFQUE | 2012-05-17 | — | — | US | disclosed |
| US-20120122913-A1 | COMBINATION OF CURCUMINOIDS AND MTOR INHIBITORS FOR THE TREATMENT OF TAUOPATHIES | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFQUE | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122913-A1 | COMBINATION OF CURCUMINOIDS AND MTOR INHIBITORS FOR THE TREATMENT OF TAUOPATHIES | MAPT, MTOR, RPTOR | GSK3B 56/4885BACE1 37/4885CYP2D6 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.